Boston University
Cutting ties with cancer: the therapeutic potential of disrupting protein-protein interactions to induce proteotoxic stress
Abstract
dc:description.abstractCancer cells exploit and rewire protein-protein interactions (PPIs) within essential cellular pathways to enable malignant transformation, uncontrolled proliferation, and resistance to cell death. This underscores the critical need to develop effective strategies that target key interactions within these pathways for the development of potent and selective inhibitors. Cancers are characterized by high levels of protein synthesis and are more susceptible to protein folding mistakes, making them rely on the activation of endoplasmic reticulum associated degradation (ERAD) to degrade these misfolded and unfolded proteins. Cancer cells leverage ERAD to maintain proteostasis and survive conditions with high cellular stress. ERAD is mediated by the interaction between the AAA-ATPase P97, ubiquitin fusion degradation protein 1 (UFD1) and nuclear protein localization protein 4 (NPL4) which together form a segregase, facilitating proteasome-mediated degradation by translocating misfolded and unfolded proteins from the ER to the cytosol. Multiple generations of P97 inhibitors have been developed to target the ATPase activity of the protein and exhibit potent preclinical anti-cancer efficacy, yet their feasibility for clinical applications remains uncertain, owing to the toxicities associated with ATP hydrolysis inhibition of P97. Here, we demonstrate that formation of the P97-UFD1-NPL4 interaction is critical for cancer cell survival while minimally required for normal cells. We developed short peptides as tools to disrupt the P97-UFD1 and UFD1-NPL4 interactions and found that targeting these interactions selectively induces a pro-apoptotic unfolded protein response (UPR) leading to cancer cell death in vitro and decreased tumor burden in vivo. Interestingly, targeting the P97-UFD1 interaction is more tolerated by zebrafish at the early embryonic development stage compared to targeting the UFD1-NPL4 heterodimer. Hence, pharmacological disruption of the P97-UFD1 interaction can serve as an alternative anticancer strategy to targeting the UPR, resulting in fewer toxicities than inhibiting the enzymatic activities of P97. In the pursuit of inhibitors targeting the P97-UFD1 interaction, we employed the Atomwise AtomNet® platform, which docked 12.5 million commercial compounds, and identified 87 compounds as potential hits. Through validation assays including biochemical and cell viability assays, as well as zebrafish xenograft assays, we narrowed down our focus to four small molecule candidates. We demonstrate that G02, H02, H08, and A’04 can disrupt the P97-UFD1 interaction leading to cancer cell death. These exciting findings pave the way for launching a new campaign of structure-activity studies and therapeutic testing for our promising small molecule hits, ushering development of selective and potent PPI inhibitors targeting the P97-UFD1-NPL4 interaction as future cancer drugs.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Pharmacology
- Grantor
- Boston University
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Kemet, Chinyere Maat
- Advisor dc:contributor.advisor
-
- Feng, Hui
- ORCID dc:identifier.orcid
Subjects
dc:subject × 9Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53151